Tvardi Therapeutics (NASDAQ:TVRD) Stock Moved Down to “Strong Sell” by Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a report released on Monday morning,Wall Street Zen reports.

Several other equities analysts have also recently issued reports on TVRD. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. BTIG Research dropped their price objective on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.40.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $1.06 on Monday. The firm has a market capitalization of $14.14 million, a price-to-earnings ratio of -0.38 and a beta of 0.38. The business’s fifty day moving average price is $1.64 and its two-hundred day moving average price is $2.54. Tvardi Therapeutics has a 52 week low of $0.93 and a 52 week high of $7.23.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, research analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Trading of Tvardi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TVRD. GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth $34,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $63,000. Finally, BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $181,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.